1 / 4

Global Retinitis Pigmentosa market size 2020

https://www.delveinsight.com/report-store/retinitis-pigmentosa-market

yashb
Download Presentation

Global Retinitis Pigmentosa market size 2020

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Retinitis Pigmentosa market report DelveInsight's Retinitis Pigmentosa Market Insights, Epidemiology, and Market Forecast- 2030 report delivers an in-depth understanding of the Retinitis Pigmentosa , historical and forecasted epidemiology as well as the Retinitis Pigmentosa market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. The Retinitis Pigmentosa market report provides current treatment practices, emerging drugs, Retinitis Pigmentosa market share of the individual therapies, current and forecasted Retinitis Pigmentosa market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Retinitis Pigmentosa treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market. Retinitis Pigmentosa Disease Understanding and Treatment Algorithm Retinitis Pigmentosa (RP) refers to a group of inherited retinal disorders causing retinal degeneration and blindness. RP is characterized by progressive bilateral degeneration of the rod and cone photoreceptors that leads to night blindness and progressive visual field defects. Individuals with RP lose their vision because of the gradual degeneration of photoreceptor (light-sensing) cells of the retina. In most forms of RP (rod-cone dystrophy), night blindness is one of the earliest and most frequent symptoms. Based on clinical impact, RP is classified into three categories that include, non-syndromic, or "simple" (not affecting other organs or tissues), Syndromic (affecting other neurosensory systems such as hearing), and Systemic (affecting multiple tissues. Non- syndromic RP has three-stage: early stage, mid and end-stage. Non-syndromic RP is

  2. further subcategorized as autosomal dominant RP, autosomal recessive RP, X-linked RP, sporadic/simplex RP, and Leber congenital amaurosis (LCA). Syndromic and Systemic RP are subcategorized into usher syndrome, bardet-biedl syndrome, and others. Diagnosis The diagnosis of RP is suspected in patients with poor night vision or family history (more than 40% of RP cases in the US have no family history). It relies upon documentation of rod dysfunction as measured by dark adaptation or electroretinogram, progressive loss in photoreceptor function, loss of peripheral vision and bilateral involvement. The most common findings on ocular examination are usually preserved visual acuity until late-stage disease and reduced visual fields. Most adult patients have posterior subcapsular cataracts and visual acuity that varies from 20/20 to near blindness late in the disease. Treatment It covers the details of conventional and current medical therapies available in the Retinitis Pigmentosa (RP) market for the treatment of the condition. It also provides the treatment guidelines and algorithms of the 7MM. The DelveInsight’s Retinitis Pigmentosa (RP) market report gives a thorough understanding of Retinitis Pigmentosa (RP) by including details such as disease definition, causes, risk factors, pathogenesis, and diagnosis. Retinitis Pigmentosa Epidemiology The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (Total Diagnosed Prevalent Cases of Retinitis Pigmentosa in the 7MM, Gender-Specific Diagnosed Prevalence of Retinitis Pigmentosa in the 7MM, Type-Specific Diagnosed Prevalence of Retinitis Pigmentosa in the 7MM, Subtype-Specific Diagnosed Prevalence of Syndromic and Systemic RP in the 7MM, and Subtype-specific Diagnosed Prevalent Cases of Non-Syndromic RP in the 7MM) scenario of Retinitis Pigmentosa in the 7MM covering United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom) and Japan from 2017–2030. Key Findings This section provides glimpses of the Retinitis Pigmentosa epidemiology in the 7MM market.

  3. According to DelveInsight’s, the total diagnosed prevalent population of Retinitis Pigmentosa (RP) in the 7MM was 253,420 in 2017. These cases are expected to increase with a significant CAGR during the study period (2017–2030). Country Wise- Retinitis Pigmentosa Epidemiology The epidemiology segment also provides the Retinitis Pigmentosa epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. Retinitis Pigmentosa Drug Chapters The drug chapter segment of the Retinitis Pigmentosa report encloses the detailed analysis of Retinitis Pigmentosa marketed drugs and late stage (phase III) pipeline drugs. It also helps to understand the RP clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases. Retinitis Pigmentosa Drug Market 1. Luxturna: Spark Therapeutics/ Novartis Luxturna (AAV2-hRPE65v2; voretigene neparvovec), known as voretigene neparvovec- rzyl, is a one-time gene therapy for the treatment of patients with vision loss due to a genetic mutation in both copies of the RPE65 gene. It provides a copy of the RPE65 gene to act in place of the mutated RPE65 gene. This working gene can restore vision and improve sight. The drug is administered as a subretinal single injection below the retina in patients who have confirmed RPE65 mutations and viable retinal cells. The drug was developed and commercialized in the US by Spark Therapeutics. In Europe, Novartis is currently marketing Luxturna as per a licensing agreement covering the development, registration and commercialization rights of Luxturna in markets outside the US. It is indicated for the treatment of patients with vision loss due to Leber’s congenital amaurosis or retinitis pigmentosa inherited retinal dystrophy caused by confirmed biallelic RPE65 mutations Retinitis Pigmentosa Market Outlook The Retinitis Pigmentosa market outlook of the report helps to build a detailed comprehension of the historic, current and forecasted Retinitis Pigmentosa market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers, and demand of better technology. This segment gives a thorough detail of Retinitis Pigmentosa market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient

  4. segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

More Related